WEBULL
News
SVRA
5.23
-1.32%
-0.07
Weekly Report: what happened at SVRA last week (0202-0206)?
Weekly Report · 14h ago
Savara Inc. nimmt an bevorstehenden Investor Healthcare Conferences teil
Reuters · 5d ago
Savara Inc. to Present at Major Investor Healthcare Conferences
Reuters · 5d ago
Expanded Hercules Credit Line Tied To MOLBREEVI Approval Could Be A Game Changer For Savara (SVRA)
Simply Wall St · 6d ago
Weekly Report: what happened at SVRA last week (0126-0130)?
Weekly Report · 02/02 09:21
Savara Inc. Highlights Leadership Team and Progress on MOLBREEVI for Autoimmune PAP in New Presentation
Reuters · 01/28 23:42
Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI
Reuters · 01/27 17:22
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit
Simply Wall St · 01/27 16:10
Savara Enters New Material Definitive Agreement and Obligation
TipRanks · 01/27 13:43
Savara Strengthens Balance Sheet With Access To ~$150M in Non-Dilutive Capital To Support MOLBREEVI Launch
Benzinga · 01/27 13:10
SAVARA ANNOUNCES AMENDMENT TO HERCULES CAPITAL DEBT FACILITY PROVIDING UP TO $75M OF ADDITIONAL DEBT FUNDING UPON U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF MOLBREEVI*
Reuters · 01/27 13:05
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 01/27 12:05
Weekly Report: what happened at SVRA last week (0119-0123)?
Weekly Report · 01/26 09:21
Assessing Savara (SVRA) Valuation As Legal Scrutiny Over MOLBREEVI Disclosures Intensifies
Simply Wall St · 01/25 23:15
Weekly Report: what happened at SVRA last week (0112-0116)?
Weekly Report · 01/19 09:23
Savara Grants Stock Options and RSUs to New Employees
Reuters · 01/16 21:05
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders
Simply Wall St · 01/16 20:12
Savara Announces New Employment Inducement Grant
Barchart · 01/16 15:05
Assessing Savara (SVRA) Valuation After MOLBREEVI Distribution Deal And FDA Priority Review Submission
Simply Wall St · 01/15 06:31
Weekly Report: what happened at SVRA last week (0105-0109)?
Weekly Report · 01/12 09:23
More
Webull provides a variety of real-time SVRA stock news. You can receive the latest news about Savara Inc through multiple platforms. This information may help you make smarter investment decisions.
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.